Xenon Pharmaceuticals (XENE) News Today $39.34 +0.49 (+1.26%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cantor Fitzgerald Analysts Cut Earnings Estimates for XENENovember 20 at 1:19 AM | americanbankingnews.comHC Wainwright Has Negative Forecast for XENE FY2024 EarningsNovember 20 at 1:19 AM | americanbankingnews.comFirst Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)First Turn Management LLC trimmed its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 325,218 sNovember 19 at 6:08 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - Here's What HappenedNovember 18 at 1:17 PM | marketbeat.comFY2024 EPS Forecast for Xenon Pharmaceuticals Cut by AnalystXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2024 EPS estimates for shares of Xenon Pharmaceuticals in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the biopharNovember 18 at 1:12 AM | marketbeat.comEquities Analysts Issue Forecasts for XENE FY2024 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for Xenon Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical compaNovember 18 at 1:12 AM | marketbeat.comXenon Pharmaceuticals' (XENE) Buy Rating Reiterated at HC WainwrightNovember 17, 2024 | americanbankingnews.comWedbush Expects Reduced Earnings for Xenon PharmaceuticalsNovember 17, 2024 | americanbankingnews.comXenon Pharmaceuticals' (XENE) "Buy" Rating Reiterated at Needham & Company LLCNovember 16, 2024 | americanbankingnews.comPromising Prospects and Strategic Advances Drive Buy Rating for Xenon PharmaceuticalsNovember 15, 2024 | markets.businessinsider.comQ1 Earnings Forecast for XENE Issued By HC WainwrightXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceuticalNovember 15, 2024 | marketbeat.comLeerink Partnrs Has Pessimistic View of XENE FY2024 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Leerink Partnrs cut their FY2024 EPS estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutNovember 15, 2024 | marketbeat.comWhat is Wedbush's Estimate for XENE FY2024 Earnings?Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at Wedbush decreased their FY2024 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Wedbush analyst L. Chico now forecasNovember 15, 2024 | marketbeat.comGSA Capital Partners LLP Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)GSA Capital Partners LLP raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 475.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,308 shares of the biopharmaceuticalNovember 14, 2024 | marketbeat.comStock Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average volume of 165 put options.November 14, 2024 | marketbeat.comXenon Pharmaceuticals: Strategic Advancements and Promising Clinical Developments Earn a Buy RatingNovember 14, 2024 | markets.businessinsider.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comXenon to Present at Upcoming Investor ConferencesNovember 13, 2024 | globenewswire.comXenon Pharmaceuticals (NASDAQ:XENE) Posts Earnings Results, Beats Estimates By $0.01 EPSXenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the business posted ($0.73) EPS.November 13, 2024 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)Needham & Company LLC reissued a "buy" rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday.November 13, 2024 | marketbeat.comXenon Pharmaceuticals Inc.: Xenon Reports Q3 2024 Financial Results and Business UpdateNovember 13, 2024 | finanznachrichten.deXenon Pharmaceuticals Reports Q3 2024 Progress and OutlookNovember 13, 2024 | markets.businessinsider.comXenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...November 13, 2024 | finance.yahoo.comXenon Advances Epilepsy and Depression ProgramsNovember 13, 2024 | markets.businessinsider.comXenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comXenon Reports Q3 2024 Financial Results and Business UpdateNovember 12, 2024 | globenewswire.comEarnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2024 ResultNovember 11, 2024 | finance.yahoo.comTimesSquare Capital Management LLC Grows Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)TimesSquare Capital Management LLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 3.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 778,293 shares ofNovember 10, 2024 | marketbeat.comFiera Capital Corp Sells 28,679 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Fiera Capital Corp trimmed its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 554,200 shares of the biopharmaceutical cNovember 9, 2024 | marketbeat.comXenon Pharmaceuticals (XENE) Set to Announce Quarterly Earnings on TuesdayXenon Pharmaceuticals (NASDAQ:XENE) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comXenon to Report Q3 2024 Financial Results on November 12, 2024November 5, 2024 | globenewswire.comHarbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Harbor Capital Advisors Inc. grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 99.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,063 shares ofNovember 5, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by abrdn plcabrdn plc lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 16.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 248,311 shares of the biopharmaceutical company's stocNovember 3, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by BrokeragesShares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have earned a consensus recommendation of "Buy" from the twelve research firms that are presently covering the firm, MarketBeat reports. Eleven analysts have rated the stock with a buy rating and one has given a strong buy ratingNovember 2, 2024 | marketbeat.comStock Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading on Wednesday. Stock traders bought 4,063 put options on the company. This represents an increase of 2,362% compared to the typical daily volume of 165 put options.October 31, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Cross Above 50 Day Moving Average - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Share Price Crosses Above 50 Day Moving Average - Should You Sell?October 29, 2024 | marketbeat.comAssenagon Asset Management S.A. Acquires 138,685 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. boosted its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 188.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 212,287 shares of theOctober 29, 2024 | marketbeat.comStrong Growth Trajectory for Xenon Driven by Promising Clinical Pipeline and Differentiation PotentialOctober 25, 2024 | markets.businessinsider.comXenon Pharmaceuticals remains a top pick into 2025 at JPMorganOctober 25, 2024 | markets.businessinsider.comSG Americas Securities LLC Sells 18,463 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)SG Americas Securities LLC cut its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 70.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,716 shares of the biopharmaceutical company's stock after selOctober 20, 2024 | marketbeat.comTraders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average daily volume of 165 put options.October 17, 2024 | marketbeat.comMillennium Management LLC Increases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Millennium Management LLC raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 109.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 175,584 shares of the biopharmaceutical company's stock after purchasing an additional 91October 11, 2024 | marketbeat.comStifel Nicolaus Remains a Buy on Xenon (XENE)October 11, 2024 | markets.businessinsider.comXenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ...October 9, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesShares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have earned a consensus recommendation of "Buy" from the eleven research firms that are currently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a buy rating and one has issued a strongOctober 8, 2024 | marketbeat.comDimensional Fund Advisors LP Raises Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Dimensional Fund Advisors LP raised its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 436,460 shares of the biopharmaceutical company'sOctober 5, 2024 | marketbeat.com43,093 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Purchased by Thrivent Financial for LutheransThrivent Financial for Lutherans bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 43,093 shares of the biopharmacOctober 3, 2024 | marketbeat.comTraders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options.October 3, 2024 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy RecommendationOctober 2, 2024 | msn.comXenon to Present at BofA Securities 2024 CNS Therapeutics Virtual ConferenceOctober 2, 2024 | globenewswire.com Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼0.070.46▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼324▲XENE Articles Average Week Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Supernus Pharmaceuticals News Sage Therapeutics News Voyager Therapeutics News Ovid Therapeutics News Marinus Pharmaceuticals News Vaxcyte News Catalent News Sarepta Therapeutics News Revolution Medicines News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
